Abstract
The liver is a common site for gastrointestinal tumor metastases as it is the first major organ reached by blood draining the portal venous system. With the development of more effective chemotherapeutic agents which may eradicate residual microscopic disease in the liver and help reduce known tumor burden, partial hepatectomy to remove gross metastatic disease will likely become increasingly utilized in the future. This chapter discusses the presentation and clinical factors in liver directed surgical resection.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jarnagin WR et al (1999) Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. J Am Coll Surg 188(1):33–42
Cancer Facts and Figures (2006) American Cancer Society
Choti MA et al (1998) Should hepatic resections be performed at high-volume referral centers? J Gastrointest Surg 2(1):11–20
Fong Y, Blumgart LH (1998) Hepatic colorectal metastasis: current status of surgical therapy. Oncology (Williston Park) 12(10): 1489–1498 (discussion 1498-500, 1503)
Jarnagin WR et al (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 236(4): 397–406 (discussion 406-7)
Adam R et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8(4):347–353
Alberts SR et al (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23(36):9243–9249
Folprecht G et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17(3):450–456
Giacchetti S et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10(6):663–669
Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
Masi G et al (2006) Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 13(1):58–65
Pozzo C et al (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15(6):933–939
Tournigand C et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24(3):394–400
Bengmark S, Hafstrom L (1969) The natural history of primary and secondary malignant tumors of the liver. II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. Digestion 2(3):179–186
Bengtsson G et al (1981) Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141(5):586–589
de Brauw LM et al (1987) Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol 34(2):81–86
Goslin R et al (1982) Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 25(8):749–754
Jaffe BM et al (1968) Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 127(1):1–11
Lewis AM, Martin RC (2006) The treatment of hepatic metastases in colorectal carcinoma. Am Surg 72(6):466–473
Finan PJ et al (1985) Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 72(5):373–377
Wood CB, Gillis CR, Blumgart LH (1976) A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2(3):285–288
Stangl R et al (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343(8910):1405–1410
Vassiliades VG, Foley WD, Alarcon J et al (1991) Hepatic metastases: CT versus MR imaging at 1.5T. Gastrointest Radiol 16:159–163
Kronawitter U et al (1999) Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma. Cancer 86(2):229–235
Povoski SP et al (1998) Role of chest CT in patients with negative chest x-rays referred for hepatic colorectal metastases. Ann Surg Oncol 5(1):9–15
Bernatik T et al (2001) Detection of liver metastases: comparison of contrast-enhanced wide-band harmonic imaging with conventional ultrasonography. J Ultrasound Med 20(5):509–515
Fong Y et al (1999) Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178(4):282–287
Akhurst T et al (2005) Recent chemotherapy reduces the sensitivity of [18F] fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23(34):8713–8716
Smith JW, Fortner JG, Burt M (1992) Resection of hepatic and pulmonary metastases from colorectal cancer. Surg Oncol 1(6):399–404
DeMatteo RP et al (2000) Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 4(2):178–184
Melendez JA et al (1998) Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 187(6):620–625
Fong Y et al (2000) Hand-assisted laparoscopic liver resection: lessons from an initial experience. Arch Surg 135(7):854–859
Koffron AJ et al. (2007) Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg 246(3): 385–392 (discussion 392-4)
Potter MW et al (2000) A critical appraisal of laparoscopic staging in hepatobiliary and pancreatic malignancy. Surg Oncol 9(3):103–110
Scheele J et al (1995) Resection of colorectal liver metastases. World J Surg 19(1):59–71
Wagner JS et al (1984) The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199(5):502–508
Tomlinson JS et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580
Pawlik TM, Schulick RD, Choti MA (2008) Expanding criteria for resectability of colorectal liver metastases. Oncologist 13(1):51–64
Azoulay D et al (2000) Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 232(5):665–672
Simmonds PC et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94(7):982–999
Shoup M et al (2003) Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7(3):325–330
Doci R et al (1991) One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 78(7):797–801
Ekberg H et al (1987) Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 11(4):541–547
Fortner JG et al (1984) Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 199(3):306–316
Hughes KS et al (1988) Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 31(1):1–4
Hughes KS et al (1986) Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100(2):278–284
Rosen CB et al (1992) Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 216(4): 493–504 (discussion 504-5)
Scheele J et al (1991) Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110(1):13–29
Zacharias T et al (2004) First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 240(5):858–865
Reddy SK et al (2007) Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol
D’Angelica M et al (1997) Ninety-six five-year survivors after liver resection for metastatic colorectal cancer. J Am Coll Surg 185(6):554–559
Fong Y et al (1994) Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 220(5):657–662
Adam R et al (1997) Repeat hepatectomy for colorectal liver metastases. Ann Surg 225(1): 51–60 (discussion 60-2)
Petrowsky H et al (2002) Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 235(6):863–871
Colucci G et al (1994) Biochemical modulation of fluorouracil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Gruppo Oncologico dell’ Italia Meridionale (GOIM). Anticancer Res 14(5B):2157–2162
Saltz LB et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905–914
Hoff PM et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19(8):2282–2292
Van Cutsem E et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097–4106
de Gramont A et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947
Goldberg RM et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30
NCCN, NCCN Clinical Practice Guidelines in Oncology. 2015
Spano JP et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16(1):102–108
Bokemeyer C et al (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22(7):1535–1546
Douillard JY et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023–1034
Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697–4705
Sorich MJ et al (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26(1):13–21
Safaee Ardekani, G et al (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7(10): e47054
Yuan ZX et al (2013) The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 8(6):e65995
Adam R et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240(6):1052–1064
Moertel CG (1987) Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5(10):1502–1522
Norheim I et al (1987) Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 206(2):115–125
Shebani KO et al (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229(6): 815–21 (discussion 822-3)
Chamberlain RS et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445
McEntee GP et al (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108(6):1091–1096
Nguyen SQ et al (2007) Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 96(5):397–403
Moertel CG et al (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120(4):302–309
Que FG et al (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169(1): 36–42 (discussion 42-3)
Sarmiento JM et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37
Yao KA et al (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130(4): 677–82 (discussion 682-5)
Touzios JG et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5): 776–83 (discussion 783-5)
Chung MH et al (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130(6):954–962
Coppa J et al (2001) Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplant Proc 33(1–2):1537–1539
Harrison LE et al (1997) Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 121(6):625–632
Earle SA et al (2006) Hepatectomy enables prolonged survival in select patients with isolated noncolorectal liver metastasis. J Am Coll Surg 203(4):436–446
Cordera F et al (2005) Hepatic resection for noncolorectal, nonneuroendocrine metastases. J Gastrointest Surg 9(9):1361–1370
Elias D et al (1995) Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol 21(5):510–513
Foster JH (1978) Survival after liver resection for secondary tumors. Am J Surg 135(3):389–394
Salmon RJ et al (1998) Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 24(2):127–130
Espat NJ (2006) Reported outcome factors for hepatic metastasectomy. J Gastrointest Surg 10(2):155–160
Adson MA et al (1984) Resection of hepatic metastases from colorectal cancer. Arch Surg 119(6):647–651
Fong Y et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15(3):938–946
Jamison RL et al (1997) Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 132(5): 505–10 (discussion 511)
Jenkins LT et al (1997) Hepatic resection for metastatic colorectal cancer. Am Surg 63(7):605–610
Bakalakos EA, Young DC, Martin EW Jr (1998) Radioimmunoguided surgery for patients with liver metastases secondary to colorectal cancer. Ann Surg Oncol 5(7):590–594
Elias D et al (1998) Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol 24(3):174–179
Choti MA et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Fernandez, R., Pappas, S.G., Bentrem, D.J. (2016). Clinical Features of Metastatic Hepatic Malignancies. In: Bentrem, D., Benson, A. (eds) Gastrointestinal Malignancies. Cancer Treatment and Research. Springer, Cham. https://doi.org/10.1007/978-3-319-34244-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-34244-3_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-34242-9
Online ISBN: 978-3-319-34244-3
eBook Packages: MedicineMedicine (R0)